ATE457725T1 - Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes - Google Patents

Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Info

Publication number
ATE457725T1
ATE457725T1 AT03789341T AT03789341T ATE457725T1 AT E457725 T1 ATE457725 T1 AT E457725T1 AT 03789341 T AT03789341 T AT 03789341T AT 03789341 T AT03789341 T AT 03789341T AT E457725 T1 ATE457725 T1 AT E457725T1
Authority
AT
Austria
Prior art keywords
kynurenine
diabetes
treatment
hydroxylase inhibitors
hydroxylase
Prior art date
Application number
AT03789341T
Other languages
English (en)
Inventor
Valerie Autier
De Vacqueur Annick Arbellot
Gerard Moinet
Dominique Marais
Catherine Kargar
Micheline Kergoat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0300107A external-priority patent/FR2849599B1/fr
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE457725T1 publication Critical patent/ATE457725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03789341T 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes ATE457725T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR0314263A FR2849598B1 (fr) 2003-01-07 2003-12-04 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
PCT/EP2003/014539 WO2004060369A1 (en) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes

Publications (1)

Publication Number Publication Date
ATE457725T1 true ATE457725T1 (de) 2010-03-15

Family

ID=32598906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789341T ATE457725T1 (de) 2003-01-07 2003-12-18 Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Country Status (17)

Country Link
US (2) US20060052456A1 (de)
EP (2) EP1581216A1 (de)
JP (2) JP4813800B2 (de)
KR (2) KR20050090447A (de)
AR (2) AR043327A1 (de)
AT (1) ATE457725T1 (de)
AU (2) AU2003296679A1 (de)
BR (2) BR0317947A (de)
CA (2) CA2512558A1 (de)
DE (1) DE60331359D1 (de)
ES (1) ES2339656T3 (de)
FR (1) FR2849598B1 (de)
MX (2) MXPA05007292A (de)
PL (2) PL376017A1 (de)
RU (2) RU2351329C2 (de)
TW (2) TW200503676A (de)
WO (2) WO2004060368A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2054056A4 (de) * 2006-08-16 2010-08-25 J David Gladstone Inst A Testa Kleinmolekulare hemmer von kynurenin-3-monooxygenase
ATE522209T1 (de) 2007-12-03 2011-09-15 Merck Patent Gmbh Verwendung von 4-oxobutansäure-derivaten bei der behandlung von mit immunologischen leiden verbundenen erkrankungen
JP5597555B2 (ja) * 2008-03-12 2014-10-01 ユニバーシティー・オブ・マイアミ 低血糖症を治療するための医薬品の製造におけるグルカゴン放出を刺激する化合物の使用
PL228037B1 (pl) * 2009-03-23 2018-02-28 Marciniak Agnieszka Maria Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki
WO2011082044A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
ES2879314T3 (es) 2010-08-18 2021-11-22 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina
PL2968249T3 (pl) 2013-02-22 2019-06-28 Samumed, Llc Gamma-diketony jako aktywatory szlaku sygnałowego Wnt/beta-kateniny
US9795550B2 (en) 2014-08-20 2017-10-24 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
EP3197466B1 (de) * 2014-09-26 2021-02-17 The University Of British Columbia Kombination aus kynurenin und antigenhaltigen zellen (apc) als therapeutika und verfahren zu deren verwendung in der immunmodulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181474A (en) * 1978-03-02 1980-01-01 Dunham-Bush, Inc. Vertical axis hermetic rotary helical screw compressor with improved rotary bearings and oil management
US5527537A (en) * 1992-05-18 1996-06-18 Dietl; Hans Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE69423343T2 (de) * 1993-12-22 2000-11-09 Entropy Systems, Inc. Anlage und verfahren für wärmeübertragung mit luft als arbeitsmedium
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
BR9707588A (pt) * 1996-02-19 1999-07-27 Japan Tobacco Inc Agente terapeutico para diabetes
JP3104966B2 (ja) * 1996-02-19 2000-10-30 日本たばこ産業株式会社 糖尿病治療薬
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
JP2004509171A (ja) * 2000-09-29 2004-03-25 ゾーン、　ロバート　ズィー． 炎症及び免疫反応の治療方法及びその組成物
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
US7727977B2 (en) 2010-06-01
FR2849598A1 (fr) 2004-07-09
RU2005125085A (ru) 2006-03-20
KR20050090447A (ko) 2005-09-13
BR0317947A (pt) 2005-11-29
JP2006516960A (ja) 2006-07-13
PL376017A1 (en) 2005-12-12
TW200503676A (en) 2005-02-01
EP1581215B1 (de) 2010-02-17
PL378212A1 (pl) 2006-03-20
DE60331359D1 (de) 2010-04-01
TW200418820A (en) 2004-10-01
FR2849598B1 (fr) 2006-09-22
JP2006515594A (ja) 2006-06-01
CA2512563A1 (en) 2004-07-22
WO2004060369A8 (en) 2005-07-07
ES2339656T3 (es) 2010-05-24
AU2003293937B2 (en) 2009-03-26
KR20050090443A (ko) 2005-09-13
WO2004060368A1 (en) 2004-07-22
US20060052456A1 (en) 2006-03-09
AR043327A1 (es) 2005-07-27
MXPA05007292A (es) 2005-09-08
US20060142358A1 (en) 2006-06-29
RU2005125086A (ru) 2006-08-27
MXPA05007293A (es) 2005-09-08
WO2004060369A1 (en) 2004-07-22
RU2351329C2 (ru) 2009-04-10
AU2003293937A1 (en) 2004-07-29
AR042712A1 (es) 2005-06-29
EP1581216A1 (de) 2005-10-05
EP1581215A1 (de) 2005-10-05
CA2512563C (en) 2012-06-19
AU2003296679A1 (en) 2004-07-29
CA2512558A1 (en) 2004-07-22
BR0317950A (pt) 2005-11-29
JP4813800B2 (ja) 2011-11-09

Similar Documents

Publication Publication Date Title
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602004014296D1 (de) Chromfreies Mittel zur Behandlung von Metalloberflächen
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1965827A4 (de) Behandlung von entmyelinisierenden erkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
DE60331359D1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE526970T1 (de) Behandlung von mastitis
DE602004026067D1 (de) Gerät zur Behandlung von Füßen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties